Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 3 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 4 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Stage 1 hypertension strongly predicts 10-year CVD events

19 May 2019

Stage 1 hypertension but not elevated blood pressure (BP) appears to be associated with a significant increase in the incidence of fatal and nonfatal cardiovascular disease (CVD) events over a 10-year follow-up, according to data from the ATTICA study.

The analysis involved 3,042 randomly selected Greek adults aged 18–89 years. Hypertension status was defined based on mean systolic/diastolic blood pressure and the most recent 2017 ACC/AHA guidelines: high normal blood pressure (HNBP; systolic, 120–139 mm Hg; diastolic, 80–89 mm Hg; no prior history of high blood pressure), elevated BP (systolic, 120–129 mm Hg; diastolic, <80 mm Hg) and stage 1 hypertension (systolic, 130–139 mm Hg; diastolic, 80–89 mm Hg).

In the cohort, the prevalence rates of HNBP, elevated BP and stage 1 hypertension were 44.6 percent (n=626), 29.0 percent (n=408) and 15.5 percent (n=218), respectively.

Incident fatal and nonfatal CVD events during follow-up of 10 years occurred in 98 patients (15.6 percent) in the HNBP group, 49 (12.0 percent) in the elevated BP group and 49 (22.5 percent) in the stage 1 hypertension group as compared with 49 (6.3 percent) in the normotension group (p<0.0001 for all).

Relative to normal BP, HNBP and stage 1 hypertension contributed to an increased risk of 10-year CVD. The risk increased by 1.5-fold with HNBP (adjusted hazard ratio [aHR], 1.49; 95 percent CI, 1.00–2.20) and by twofold with stage 1 hypertension (aHR, 1.90; 1.16–3.08). The risk increase was particularly pronounced in males (aHR, 2.03; 1.08–3.83).

On the other hand, elevated BP was not associated with an increased risk of developing 10-year CVD events (aHR, 1.28; 0.82–2.02).

In light of a notable increased risk of 10-year fatal and nonfatal CVD events associated with HNBP and stage 1 hypertension, researchers called for the implementation of targeted primary and secondary prevention interventions that may deter both CVD and related adverse health outcomes.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 3 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 4 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.